First oral GLP-1 treatment for weight management

Overview of (invented) names reviewed in April 2026 by the Name Review Group (NRG) adopted at the CHMP meeting of 21 May 2026

Human medicines European public assessment report (EPAR): Deqtynet, copper (64Cu) oxodotreotide, Status: Opinion

Human medicines European public assessment report (EPAR): Ablymico, liraglutide, Status: Opinion

Human medicines European public assessment report (EPAR): Liraglutide STADA, liraglutide, Status: Opinion

Human medicines European public assessment report (EPAR): Orblid, bevacizumab, Status: Application withdrawn

Human medicines European public assessment report (EPAR): Veblocema, infliximab, Status: Application withdrawn

Human medicines European public assessment report (EPAR): Vislyfa, ranibizumab, Status: Opinion

Human medicines European public assessment report (EPAR): Etcamah, camizestrant, Status: Opinion

Summary of opinion: Trodelvy, 21/05/2026 Positive